Imunon (IMNN) Non-Current Debt (2010 - 2023)
Imunon's (IMNN) quarterly Non-Current Debt came in at $3.9 million in Q1 2023, down 33.91% YoY from $5.9 million in Q1 2022, and down 15.44% on a QoQ basis from $4.6 million in Q4 2022.
Imunon (IMNN) Non-Current Debt (2010 - 2023) Analysis & Trends
Imunon (IMNN) has 14 years of Non-Current Debt data on file, last reported at $3.9 million in Q1 2023.
- Quarterly Non-Current Debt fell 33.91% year-over-year to $3.9 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $3.9 million (down 33.91% YoY) and the FY2022 annual result came in at $4.6 million, down 21.24% from the prior year.
- Non-Current Debt eased to $3.9 million in Q1 2023, from $4.6 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $9.6 million in Q2 2019 to a low of $3.3 million in Q1 2021.
- A 5-year average of $6.1 million and a median of $5.8 million in 2021 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2021 — Non-Current Debt tumbled 57.34% — and 2022, when it surged 81.42%.
- Tracing IMNN's Non-Current Debt over 5 years: stood at $8.0 million in 2019, then plunged by 50.59% to $3.9 million in 2020, then soared by 48.8% to $5.9 million in 2021, then slipped by 21.24% to $4.6 million in 2022, then declined by 15.44% to $3.9 million in 2023.
- The last three Non-Current Debt figures came in at $3.9 million (Q1 2023), $4.6 million (Q4 2022), and $5.3 million (Q3 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3.90 Mn |
| Dec 31, 2022 | 4.61 Mn |
| Sep 30, 2022 | 5.32 Mn |
| Jun 30, 2022 | 5.95 Mn |
| Mar 31, 2022 | 5.90 Mn |
| Dec 31, 2021 | 5.85 Mn |
| Sep 30, 2021 | 5.81 Mn |
| Jun 30, 2021 | 5.76 Mn |
| Mar 31, 2021 | 3.25 Mn |
| Dec 31, 2020 | 3.93 Mn |
| Sep 30, 2020 | 4.63 Mn |
| Jun 30, 2020 | 5.61 Mn |
| Mar 31, 2020 | 7.62 Mn |
| Dec 31, 2019 | 7.96 Mn |
| Sep 30, 2019 | 9.13 Mn |
| Jun 30, 2019 | 9.61 Mn |
| Mar 31, 2019 | 9.51 Mn |
| Dec 31, 2018 | 9.42 Mn |
| Sep 30, 2018 | 9.32 Mn |
| Jun 30, 2018 | 9.22 Mn |